TY - JOUR
T1 - Fatigability, Exercise Intolerance, and Abnormal Skeletal Muscle Energetics in Heart Failure
AU - Weiss, Kilian
AU - Schär, Michael
AU - Panjrath, Gurusher S.
AU - Zhang, Yi
AU - Sharma, Kavita
AU - Bottomley, Paul A.
AU - Golozar, Asieh
AU - Steinberg, Angela
AU - Gerstenblith, Gary
AU - Russell, Stuart D.
AU - Weiss, Robert G.
N1 - Funding Information:
This study was supported by the following National Institutes of Health grants: HL61912, HL63030, and AG045634.
Publisher Copyright:
© 2017 American Heart Association, Inc.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Background Among central and peripheral factors contributing to exercise intolerance (EI) in heart failure (HF), the extent to which skeletal muscle (SM) energy metabolic abnormalities occur and contribute to EI and increased fatigability in HF patients with reduced or preserved ejection fraction (HFrEF and HFpEF, respectively) are not known. An energetic plantar flexion exercise fatigability test and magnetic resonance spectroscopy were used to probe the mechanistic in vivo relationships among SM high-energy phosphate concentrations, mitochondrial function, and EI in HFrEF and HFpEF patients and in healthy controls. Methods and Results Resting SM high-energy phosphate concentrations and ATP flux rates were normal in HFrEF and HFpEF patients. Fatigue occurred at similar SM energetic levels in all subjects, consistent with a common SM energetic limit. Importantly, HFrEF New York Heart Association class II-III patients with EI and high fatigability exhibited significantly faster rates of exercise-induced high-energy phosphate decline than did HFrEF patients with low fatigability (New York Heart Association class I), despite similar left ventricular ejection fractions. HFpEF patients exhibited severe EI, the most rapid rates of high-energy phosphate depletion during exercise, and impaired maximal oxidative capacity. Conclusions Symptomatic fatigue during plantar flexion exercise occurs at a common energetic limit in all subjects. HFrEF and HFpEF patients with EI and increased fatigability manifest early, rapid exercise-induced declines in SM high-energy phosphates and reduced oxidative capacity compared with healthy and low-fatigability HF patients, suggesting that SM metabolism is a potentially important target for future HF treatment strategies.
AB - Background Among central and peripheral factors contributing to exercise intolerance (EI) in heart failure (HF), the extent to which skeletal muscle (SM) energy metabolic abnormalities occur and contribute to EI and increased fatigability in HF patients with reduced or preserved ejection fraction (HFrEF and HFpEF, respectively) are not known. An energetic plantar flexion exercise fatigability test and magnetic resonance spectroscopy were used to probe the mechanistic in vivo relationships among SM high-energy phosphate concentrations, mitochondrial function, and EI in HFrEF and HFpEF patients and in healthy controls. Methods and Results Resting SM high-energy phosphate concentrations and ATP flux rates were normal in HFrEF and HFpEF patients. Fatigue occurred at similar SM energetic levels in all subjects, consistent with a common SM energetic limit. Importantly, HFrEF New York Heart Association class II-III patients with EI and high fatigability exhibited significantly faster rates of exercise-induced high-energy phosphate decline than did HFrEF patients with low fatigability (New York Heart Association class I), despite similar left ventricular ejection fractions. HFpEF patients exhibited severe EI, the most rapid rates of high-energy phosphate depletion during exercise, and impaired maximal oxidative capacity. Conclusions Symptomatic fatigue during plantar flexion exercise occurs at a common energetic limit in all subjects. HFrEF and HFpEF patients with EI and increased fatigability manifest early, rapid exercise-induced declines in SM high-energy phosphates and reduced oxidative capacity compared with healthy and low-fatigability HF patients, suggesting that SM metabolism is a potentially important target for future HF treatment strategies.
KW - magnetic resonance imaging
KW - magnetic resonance spectroscopy
KW - skeletal muscle
UR - http://www.scopus.com/inward/record.url?scp=85024890219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024890219&partnerID=8YFLogxK
U2 - 10.1161/CIRCHEARTFAILURE.117.004129
DO - 10.1161/CIRCHEARTFAILURE.117.004129
M3 - Article
C2 - 28705910
AN - SCOPUS:85024890219
SN - 1941-3297
VL - 10
JO - Circulation: Heart Failure
JF - Circulation: Heart Failure
IS - 7
M1 - e004129
ER -